This Is MS Multiple Sclerosis Knowledge & Support Community

Biogen Idec and Elan Corporation, plc have announced six-month results of an ongoing, one-year longitudinal, observational, patient-reported outcomes study showing multiple sclerosis (MS) patients taking Tysabri® (natalizumab) experienced an improvement in both their physical function and psychological well-being.

Findings from the study, which was performed in conjunction with HealthCore Inc., a health-outcomes research company, are the first attempt to assess patient experiences with Tysabri in usual-care settings. The data, presented at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), shows patients report Tysabri has an impact in improving their overall quality of life.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1768

Healthcore is a large shareholder in Biogen/Idec and less than a year ago, publicly attacked James Mullen, Biogen's CEO, for selling massive amounts of stock for his personal gain...thus reducing the value of the company's shares.

Perhaps these testing results may be an attempt to bolster Tysabri's sales and improve the financial situation at Biogen. Just a thought.

Harry